The FDA's Priority Review for Vyvgart's label expansion in myasthenia gravis accelerates Argenx's growth strategy, while investors weigh the company's broader pipeline against its current valuation.
Netflix shares have tumbled from recent highs amid investor skepticism over a potential $72 billion acquisition. Despite the sell-off, some Wall Street firms are upgrading the stock, citing strong fundamentals and a historically attractive valuation.
Analyst Quinn Bolton of Needham maintains a Buy rating on D-Wave Quantum (QBTS), highlighting the company's strengthened competitive position after its acquisition of Quantum Circuits, which creates the world's only dual-platform quantum computing firm.
As demand surges post-pandemic, Royal Caribbean Group is committing billions to new ships and destinations. CFO Naftali Holtz details the balancing act between ambitious growth, shareholder returns, and leveraging AI to enhance the passenger experience.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
A wave of subscription increases from Netflix, Disney, Apple, and others is forcing consumers to rethink their streaming budgets, with ad-supported tiers and strategic bundling emerging as key cost-saving strategies.
After the COVID-19 windfall subsided, Pfizer CEO Albert Bourla is steering the pharmaceutical giant into a high-stakes, $23 billion pivot to cancer research. Facing a looming patent cliff and plummeting vaccine revenue, Bourla is betting on scientific innovation to secure the company's future—and redefine cancer treatment.
In a significant shift from its long-standing marketing playbook, Pizza Hut will not advertise during NBC's Super Bowl pre-game coverage this year, ending a tradition that spanned over a decade. The move comes as the chain undergoes a strategic review and reallocates its ad budget toward other sports and partnerships.
While the healthcare sector has significantly outperformed the broader market, surging 17.4% in six months, not all companies are positioned to thrive. Intense competition and shifting market dynamics pose risks for some established players. We examine three stocks where investors may want to exercise caution.
While the healthcare sector has surged 17.4% in six months, outpacing the S&P 500, regulatory headwinds and valuation concerns demand a selective approach. We examine one stock with a durable edge and two facing significant challenges.
Generating cash is just the first step. We analyze three companies to see which ones effectively convert that cash into lasting shareholder value and which ones struggle to capitalize on their financial strength.
While robust cash generation is a hallmark of a healthy business, it doesn't automatically translate to a sound investment. We examine three companies with strong free cash flow margins where valuation and strategic concerns give investors pause.
Netflix shares face pressure as the streaming giant's 2026 revenue guidance signals a significant growth deceleration, even with its advertising business poised to double. Investor concerns are compounded by a potential multi-billion dollar acquisition.
Guggenheim Securities has initiated coverage of clinical-stage biopharma AtaiBeckley with a Buy rating and an $11 price target, highlighting its leadership in next-generation psychiatric treatments following its merger with Beckley Psytech.
As SpaceX reportedly engages banks for a potential 2026 public offering, the pre-IPO secondary market for late-stage tech giants is booming, offering a critical liquidity valve and reshaping the path to going public.
Cocoa prices staged a modest technical rebound on Friday, halting a month-long slide that had pushed contracts to their lowest levels in over two years. The move higher, driven by short-covering in an oversold market, comes amid a complex backdrop of abundant near-term supplies, weakening demand, and a tightening longer-term outlook.
A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.
A trove of documents released by the U.S. Department of Justice includes emails from Jeffrey Epstein making lurid, unsubstantiated allegations about Bill Gates, while also detailing his interactions with other prominent individuals.
A pivotal week for prediction markets saw Coinbase partner with Kalshi to offer event contracts nationwide, while the CFTC moved to establish clearer regulatory standards. Meanwhile, traders sharply increased bets on a potential U.S. government shutdown.
Sanofi announces promising late-stage results for its immunology candidate amlitelimab and expands into genetic therapies via an investment in Sensorion, signaling a strategic push into high-value therapeutic areas.
